Trial reportBMC cancer2026
Peripheral monocyte ratio as a predictive biomarker for metastasis-directed therapy in prostate cancer: insights from an exploratory study.
Trial report in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
introductionTraditionally, androgen deprivation therapy (ADT) alone was the standard treatment for oligometastatic prostate cancer. However, stereotactic body radiotherapy (SBRT) for metastasis-directed therapy (MDT) in the hormone sensitive setting is demonstrating improved outcomes. Despite this, not all patients will experience a durable response to MDT. The discovery of pre-treatment biomarkers to predict patient outcomes are needed to further improve management in this setting.
methodsIn this randomized study, peripheral blood mononuclear cells were collected and analyzed using flow cytometry from 26 hormone sensitive oligometastatic prostate cancer patients that were recruited and randomly assigned to receive either intermittent androgen deprivation therapy (iADT) alone or MDT in the form of iADT+SBRT as part of a larger clinical trial.
resultsIn patients treated with MDT, a high peripheral ratio of CD14high (classical) to CD14low (non-classical) monocytes at pre-treatment was significantly associated with complete biochemical response (PSA becoming ≤ 0.02 ng/mL) and freedom from biochemical progression (PSA nadir + 2 ng/mL). In contrast, the association was absent in patients treated with iADT alone, suggesting that SBRT may play a significant role in mounting an immune response, resulting in improved oncological outcomes. Furthermore, single-cell RNA sequencing of prostate cancer metastases suggested that classical monocytes from early responder patients may exhibit an elevated pro-inflammatory and chemokine-responsive transcriptional program.
conclusionsTogether, these preliminary findings suggest the potential of monocyte ratios as an early predictive biomarker for MDT. If validated, this could potentially identify poor responders to MDT for consideration of additional systemic treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.